Avidity Partners Management LP Century Therapeutics, Inc. Transaction History

Avidity Partners Management LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$3.19 - $5.32 $425,689 - $709,927	-133,445 Reduced 9.85%	1,221,555 $5.11 Million
Q4 2023 Feb 14, 2024	BUY	$1.28 - $3.32 $328,320 - $851,580	256,500 Added 23.35%	1,355,000 $4.5 Million
Q3 2023 Nov 14, 2023	SELL	$2.0 - $3.23 $24,800 - $40,052	-12,400 Reduced 1.12%	1,098,500 $2.2 Million
Q2 2023 Aug 14, 2023	SELL	$2.91 - $3.53 $457,452 - $554,916	-157,200 Reduced 12.4%	1,110,900 $3.51 Million
Q1 2023 May 15, 2023	SELL	$3.4 - $5.11 $120,700 - $181,405	-35,500 Reduced 2.72%	1,268,100 $4.4 Million
Q3 2022 Nov 14, 2022	BUY	$8.57 - $13.1 $3.76 Million - $5.75 Million	438,600 Added 50.71%	1,303,600 $12.9 Million
Q1 2022 May 16, 2022	BUY	$11.62 - $15.92 $156,614 - $214,569	13,478 Added 1.58%	865,000 $10.9 Million
Q4 2021 Feb 14, 2022	BUY	$13.93 - $23.62 $1.56 Million - $2.65 Million	112,253 Added 15.18%	851,522 $13.5 Million
Q3 2021 Nov 15, 2021	SELL	$20.8 - $31.93 $5.5 Million - $8.44 Million	-264,253 Reduced 26.33%	739,269 $18.6 Million
Q2 2021 Aug 16, 2021	BUY	$22.45 - $29.34 $22.5 Million - $29.4 Million	1,003,522 New	1,003,522 $29.4 Million

36.9M

8.7K

10.2K

Ticker IPSC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,881,800
Market Cap $74.2M
Description
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 fo...

Get notified when there are updates to the investment portfolio of Avidity Partners Management LP, based on Form 13F filings with the SEC.

Stay updated on Avidity Partners Management LP with notifications on news.